This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALDR Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Alder Biopharmaceuticals Stock (NASDAQ:ALDR) 30 days 90 days 365 days Advanced Chart Get ALDR alerts:Sign Up Key Stats Today's Range$18.88▼$18.8850-Day Range$18.88▼$18.8852-Week Range$8.39▼$19.12VolumeN/AAverage Volume5.12 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Read More Receive ALDR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDR Stock News HeadlinesAlder Hey hospital issues urgent open letter as 'several children seriously unwell'July 7 at 7:17 PM | msn.comChildren 'seriously unwell' at Alder Hey as hospital issues urgent message to Merseyside parentsJuly 7 at 7:17 PM | msn.comF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.July 8 at 2:00 AM | The Tomorrow Investor (Ad)Alder Hey hospital issues rare letter to parents after children left 'very unwell'July 7 at 7:17 PM | mirror.co.ukMAlder Springs Fire latest: Evacuation orders drop to Level 1 as rain gives wildland firefighters helpJune 21, 2025 | msn.comAlder Springs Fire in central Oregon grows to 3,442 acresJune 20, 2025 | msn.comAlder Springs Fire determined to be human caused, fire mapped at 3,442 acresJune 19, 2025 | msn.comAlder Hey Children's Hospital: all the key numbers for the NHS Trust in March, as think tank warns efforts to reduce patients waits are "stalling"May 16, 2025 | msn.comSee More Headlines ALDR Stock Analysis - Frequently Asked Questions How were Alder Biopharmaceuticals' earnings last quarter? Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.01. What other stocks do shareholders of Alder Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/07/2018Today7/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDR CIK1423824 Webwww.alderbio.com Phone425-205-2900FaxN/AEmployees202Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-226.13% Return on Assets-66.86% Debt Debt-to-Equity Ratio1.74 Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$1.62 million Price / Sales977.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book11.73Miscellaneous Outstanding Shares83,840,000Free FloatN/AMarket Cap$1.58 billion OptionableOptionable Beta2.64 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ALDR) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alder Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alder Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.